Thomas P. Conrads
Louisiana State University, National Cancer Institute, National Institutes of Health
Papers
3
Total Citations
151
H-Index
3
About
Thomas P. Conrads is a biomedical researcher whose work spans proteomics, cancer diagnostics, and biochemical technology development. He is perhaps best recognized for his contributions to serum proteomic profiling as a diagnostic tool for prostate cancer. His landmark 2004 study demonstrated that artificial intelligence-driven pattern recognition algorithms, applied to surface-enhanced laser desorption ionization time-of-flight mass spectrometry data, could effectively discriminate prostate cancer from benign conditions in patients with ambiguous PSA levels between 2.5 and 15.0 ng/mL — a clinically challenging diagnostic range. This work garnered 114 citations, underscoring its significance in the field of cancer biomarker discovery. Beyond diagnostics, Conrads has contributed to advancing peptide array technologies, developing fully automated synthesis platforms for phosphopeptide arrays that streamline protein tyrosine kinase characterization. He has also pioneered innovative proteomic tools such as Pooled ORF Expression Technology (POET), which integrates recombinational cloning with mass spectrometry to optimize soluble protein production. Together, these contributions reflect a career dedicated to building and applying cutting-edge proteomic methodologies to both fundamental biological questions and translational clinical challenges in cancer research.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3Pooled ORF Expression Technology (POET)11 citations · 2005